U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C8H9FN2O3
Molecular Weight 200.1671
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of TEGAFUR, (S)-

SMILES

FC1=CN([C@@H]2CCCO2)C(=O)NC1=O

InChI

InChIKey=WFWLQNSHRPWKFK-LURJTMIESA-N
InChI=1S/C8H9FN2O3/c9-5-4-11(6-2-1-3-14-6)8(13)10-7(5)12/h4,6H,1-3H2,(H,10,12,13)/t6-/m0/s1

HIDE SMILES / InChI

Molecular Formula C8H9FN2O3
Molecular Weight 200.1671
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 1 / 1
E/Z Centers 0
Optical Activity UNSPECIFIED

Approval Year

PubMed

PubMed

TitleDatePubMed
Pathologic downstaging of T3-4Nx rectal cancer after chemoradiation: 5-fluorouracil vs. Tegafur.
2001-12-01
Phase I trial of weekly irinotecan combined with UFT as second-line treatment for advanced colorectal cancer.
2001-12
A comparative study of subcutaneous mastectomy with radical mastectomy.
2001-11-20
Fluorouracil (5FU) pharmacokinetics in 5FU prodrug formulations with a dihydropyrimidine dehydrogenase inhibitor.
2001-11-15
[A case of squamous cell carcinoma of the oral floor showing a complete response to oral administration of UFT].
2001-11
[A complete response persisting for twelve months with the use of TS-1 in a patient with paraaortic lymph node metastasis of gastric cancer].
2001-11
[A case of postoperative gastric cancer responding to adjuvant chemotherapy with TS-1--a novel oral formation of 5-fluorouracil].
2001-11
[A case of breast cancer with multiple metastases effectively treated with long-term administration of docetaxel, aclarubicin and UFT].
2001-11
[Dihydropyrimidine dehydrogenase activity in urothelial cancer--influence of UFT administration on DPD activity].
2001-11
Plasma, intestine and tumor levels of 5-fluorouracil in mice bearing L1210 ascites tumor following oral administration of 5-fluorouracil, UFT (mixed compound of tegafur and uracil), carmofur and 5'-deoxy-5-fluorouridine.
2001-11
The role of UFT and the combination of UFT/leucovorin in non-small cell lung cancer.
2001-11
[New therapeutic options in chemotherapy of advanced colorectal cancer].
2001-10-15
Early phase II study of S-1, a new oral fluoropyrimidine, for advanced non-small-cell lung cancer.
2001-10
Combined effects of docetaxel and fluoropyrimidines on tumor growth and expression of interleukin-6 and thymidine phosphorylase in breast cancer xenografts.
2001-10
[Sigmoid colon cancer with multiple liver metastasis (H3) effectively treated with CPT-11 and DSM (degradable starch microsphere) HAI therapy and intensive high dosage 5-FU HAI therapy--a case report].
2001-10
[Efficacy of intraperitoneal chemotherapy for peritoneal recurrence of gastric carcinoma].
2001-10
Nonsurgical treatment of hepatocellular carcinoma.
2001-10
[A case report of rectal cancer with liver and pulmonary metastases responding to TS-1].
2001-10
[A case of remnant gastric cancer responding to neoadjuvant TS-1 therapy].
2001-10
[Case report: a recurrent gastric cancer in the terminal stage, associated with obstructive jaundice which responded significantly to oral administration of TS-1].
2001-10
[Complete response in a case of advanced gastric cancer with liver and intra-abdominal lymph node metastases treated by combined chemotherapy of TS-1 and CDDP].
2001-10
[A pilot study of low-dose TS-1 and cisplatin combination chemotherapy for advanced gastric cancer].
2001-10
[A new therapeutic approach to advanced and recurrent gastric cancer by TS-1].
2001-10
[Late phase II study of S-1 in patients with advanced head and neck cancer].
2001-10
Phase II study of S-1, a novel oral fluorouracil, in advanced non-small-cell lung cancer.
2001-09-28
Complete response achieved following administration of S-1 in a patient with adrenal gland metastasis of 5-FU-resistant gastric cancer: a case report.
2001-09
Oral uracil-tegafur: an alternative to intravenous 5-fluorouracil?
2001-09
UFT and leucovorin in first-line chemotherapy for patients with metastatic gastric cancer. An Early Clinical Studies Group (ECSG)/European Organization for Research Treatment of Cancer (EORTC) phase II trial.
2001-09
New drugs and combinations in the palliative treatment of colon and rectal cancer.
2001-09
Possible regulation of 5-fluorouracil-induced neuro- and oral toxicities by two biochemical modulators consisting of S-1, a new oral formulation of 5-fluorouracil.
2001-08-11
Efficacy of oral UFT plus leucovorin therapy for colon cancer with ovarian and multiple liver metastases: report of two cases.
2001-08-10
Simultaneous determination of F-beta-alanine and beta-alanine in plasma and urine with dual-column reversed-phase high-performance liquid chromatography.
2001-08-05
New options for outpatient chemotherapy--the role of oral fluoropyrimidines.
2001-08
[A case of nonresectable scirrhous type gastric cancer treated by hypertensive subselective chemotherapy with pharmacokinetic modulating chemotherapy].
2001-08
[A case of hepatic metastasis of gastric cancer responding to TS-1, administered for two consecutive weeks and one week rest].
2001-08
[Postoperative chemotherapy with a novel oral anticancer drug composed of tegafur, gimeracil and oteracil potassium to curability C scirrhus type gastric cancer].
2001-08
Changes in intratumoral thymidylate synthase (TS) and dihydropyrimidine dehydrogenase (DPD) mRNA expression in colorectal and gastric cancer during continuous tegafur infusion.
2001-08
A phase II study of combined oral uracil and ftorafur with leucovorin for patients with squamous cell carcinoma of the head and neck.
2001-07-15
[A case of advanced gastric cancer that was resectable after asctic fluid had disappeared following administration of TS-1].
2001-07
[A case of advanced gastric cancer with multiple liver metastases in an elderly patient that responded dramatically to UFT therapy].
2001-07
[Two elderly patients with advanced gastric cancer responding to chronomodulation chemotherapy with tegafur + cisplatin + isovorin followed by oral administration of S-1].
2001-07
Adjuvant chemotherapy after resection of hepatocellular carcinoma causes deterioration of long-term prognosis in cirrhotic patients: metaanalysis of three randomized controlled trials.
2001-06-15
Phase II trial of epirubicin, cisplatin, oral uracil and tegafur, and leucovorin in patients with advanced gastric carcinoma.
2001-06-15
Cutaneous metastases from gastric adenocarcinoma treated with combination chemotherapy producing complete response with long survival.
2001-06
Interstitial pneumonia possibly due to a novel anticancer drug, TS-1: first case report.
2001-06
[New oral anticancer drug, TS-1 (S-1)--from bench to clinic].
2001-06
[TS-1 therapy for advanced gastric cancer].
2001-04
Answering patients' needs: oral alternatives to intravenous therapy.
2001
[Experimental study of radiosensitizing effect of analogs of purines and pyrimidine bases in cultured HeLa cells].
2001
Complete response of highly advanced gastric cancer with peritoneal dissemination after new combined chemotherapy of S-1 and low-dose cisplatin: report of a case.
2001
Patents
Substance Class Chemical
Created
by admin
on Mon Mar 31 22:53:28 GMT 2025
Edited
by admin
on Mon Mar 31 22:53:28 GMT 2025
Record UNII
4D5LOR404U
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
TEGAFUR, (S)-
Common Name English
(S)-FTORAFUR
Preferred Name English
2,4(1H,3H)-PYRIMIDINEDIONE, 5-FLUORO-1-((2S)-TETRAHYDRO-2-FURANYL)-
Systematic Name English
Code System Code Type Description
FDA UNII
4D5LOR404U
Created by admin on Mon Mar 31 22:53:28 GMT 2025 , Edited by admin on Mon Mar 31 22:53:28 GMT 2025
PRIMARY
PUBCHEM
148755
Created by admin on Mon Mar 31 22:53:28 GMT 2025 , Edited by admin on Mon Mar 31 22:53:28 GMT 2025
PRIMARY
CAS
55774-30-6
Created by admin on Mon Mar 31 22:53:28 GMT 2025 , Edited by admin on Mon Mar 31 22:53:28 GMT 2025
PRIMARY